Eligard Suppresses Testosterone in Up to 98% of Men, but the Dosing Schedule Matters
Eligard works as a GnRH agonist (gonadotropin-releasing hormone agonist), which essentially tricks the brain's hormonal signaling system into shutting down testosterone production. It uses a polymer gel called Atrigel that forms a small biodegradable implant under the skin, slowly releasing leuprolide over weeks or months depending on the formulation.
How the Different Dosing Options Compare
Eligard comes in three main subcutaneous depot formulations. Each delivers a different amount of drug over a different window:
| Formulation | Dose | Injection Frequency | Testosterone Suppression (≤20 ng/dL) |
|---|---|---|---|
| 1-month depot | 7.5 mg | Every month | 94–98% |
| 3-month depot | 22.5 mg | Every 3 months | 94–98% |
| 6-month depot | 45 mg | Every 6 months | ~88–90% |
The 1-month and 3-month versions perform nearly identically, with almost no testosterone "breakthroughs" reported in trials. The 6-month depot is still effective for most men, but that slightly lower suppression rate is a real tradeoff for the convenience of fewer injections.
PSA (prostate-specific antigen) tells a similar story. With the 6-month depot, PSA dropped roughly 82–99% over 12 to 24 months in trials and registries. In routine clinical practice across Brazil, Germany, and Russia, large real-world cohorts showed PSA reductions of 80–96% or higher, with good tolerability.
What Side Effects to Expect
The side effects of Eligard are mostly what you'd predict from drastically lowering testosterone. The most common include:
- Hot flushes
- Sexual dysfunction
- Injection-site reactions
These are generally rated mild to moderate in clinical studies. Large observational studies put the rate of serious treatment-related events at roughly 1–9%, which is relatively low for a long-term cancer therapy.
One rare but notable reaction deserves mention: systemic allergic contact dermatitis triggered by N-methyl-2-pyrrolidone, a solvent used in the Atrigel delivery system. This is uncommon enough to be reported as a case study rather than a population-level finding, but worth flagging if you develop an unusual skin reaction after injection.
Beyond Prostate Cancer
The research on Eligard outside of prostate cancer is thin but interesting in two areas.
First, a clinical trial called LUCINDA is testing Eligard combined with donepezil (a common Alzheimer's medication) to see if the combination slows cognitive decline in women with Alzheimer's disease. Results aren't available yet, so this remains firmly in the "being investigated" category.
Second, Eligard is used for puberty suppression in transgender and gender diverse youth. When compared to intramuscular Lupron (another leuprolide formulation), both achieved clinical suppression, but Eligard showed slightly higher rates of biochemical suppression. The available research doesn't go into detail about how large that difference is or what it means long-term.
Choosing Your Dosing Schedule
If you're facing a decision about Eligard, the practical question is really about the tradeoff between convenience and consistency of suppression.
| Priority | Best Fit | Why |
|---|---|---|
| Maximum testosterone suppression | 1-month or 3-month depot | 94–98% suppression, almost no breakthroughs |
| Fewer clinic visits | 6-month depot | Only two shots per year, but ~88–90% suppression |
| Balance of both | 3-month depot | Strong suppression with only four visits per year |
The 3-month formulation looks like the sweet spot for most people: it matches the shorter depot's suppression rates while cutting clinic visits to four times a year. The 6-month option makes sense if logistics are a real barrier, but the slightly lower suppression rate is something to discuss with your oncologist, particularly if your PSA response is being closely monitored.
The evidence across trials and large real-world cohorts consistently supports Eligard as effective and well-tolerated. The side effects are real but predictable, and serious reactions are uncommon. The biggest variable in your control is which schedule fits your life and your treatment goals.
